Similar articles

• Perspectives on a time-dependent model of neuroleptic action.

  Pickar D. Pickar D. Schizophr Bull. 1988;14(2):255-68. doi: 10.1093/schbul/14.2.255. Schizophr Bull. 1988. PMID: 2904694 Review.
• Effects of mianserin on negative symptoms in schizophrenia.

  Mizuki Y, Kajimura N, Imai T, Suetsugi M, Kai S, Kaneyuki H, Yamada M. Mizuki Y, et al. Int Clin Psychopharmacol. 1990 Apr;5(2):83-95. doi: 10.1097/00004850-199004000-00002. Int Clin Psychopharmacol. 1990. PMID: 1696292
• Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.

  Koshikawa H, Suzuki E, Kanba S, Nibuya M, Ishizuki T, Kohno H, Kinoshita N, Shintani F, Yagi G, Nakaki T, et al. Koshikawa H, et al. Yakubutsu Seishin Kodo. 1991 Feb;11(1):79-81. Yakubutsu Seishin Kodo. 1991. PMID: 1679276 Clinical Trial. No abstract available.
• Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.

  Suzuki E, Kanba S, Nibuya M, Adachi S, Sekiya U, Shintani F, Kinoshita N, Yagi G, Asai M. Suzuki E, et al. Biol Psychiatry. 1994 Nov 15;36(10):654-61. doi: 10.1016/0006-3223(94)91174-6. Biol Psychiatry. 1994. PMID: 7880934
• Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.

  Wiesel FA. Wiesel FA. Br J Psychiatry Suppl. 1994 Apr;(23):65-70. Br J Psychiatry Suppl. 1994. PMID: 7913610 Review.